Concert Pharmaceuticals, Inc.
CNCE
CNCE was delisted on the 3rd of March, 2023.
94 hedge funds and large institutions have $132M invested in Concert Pharmaceuticals, Inc. in 2016 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 31 increasing their positions, 37 reducing their positions, and 10 closing their positions.
700% more call options, than puts
Call options by funds: $160K | Put options by funds: $20K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
3% less funds holding
Funds holding: 97 → 94 (-3)
14% less capital invested
Capital invested by funds: $154M → $132M (-$21.8M)
16% less repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 37
30% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alyeska Investment Group
Chicago,
Illinois
|
+$3.61M |
| 2 |
ISL
Ingalls & Snyder LLC
New York
|
+$2.95M |
| 3 |
Renaissance Technologies
New York
|
+$1.77M |
| 4 |
SCA
Secor Capital Advisors
New York
|
+$800K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$655K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SAM
Senzar Asset Management
New York
|
-$2.5M |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
-$2.29M |
| 3 |
Millennium Management
New York
|
-$1.83M |
| 4 |
BBA
Baker Bros. Advisors
New York
|
-$1.67M |
| 5 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$1.6M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AIM
101
Acrospire Investment Management
Chicago,
Illinois
| – | -$32K | -2,812 | Closed |
|
102
Teacher Retirement System of Texas
Austin,
Texas
| – | -$23K | -2,016 | Closed |
|
103
Bank of Montreal
Toronto,
Ontario, Canada
| – | -$18K | -1,616 | Closed |
|
|
BJ
104
BlackRock Japan
Tokyo,
Japan
| – | -$11K | -998 | Closed |
|
CNCE Hedge Fund Activity: Q3 2016 in Review
94 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Concert Pharmaceuticals, Inc. (CNCE) for Q3 2016, worth a combined $132M — down 14% from $154M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of CNCE and 7 opened new positions — a net loss of 3 holders — while 37 trimmed existing stakes and 31 added.
The largest buyer was Alyeska Investment Group, opening a new position worth an estimated $3.61M. The largest seller was Senzar Asset Management, cutting an estimated $2.5M.
- 94 institutional investors held Concert Pharmaceuticals, Inc. (CNCE) as of Q3 2016, down from 97 in Q2 2016.
- Funds reported $132M of Concert Pharmaceuticals, Inc. stock for Q3 2016, down 14% quarter-over-quarter.
- 7 funds opened new Concert Pharmaceuticals, Inc. positions in Q3 2016 and 10 closed out, a net change of -3 holders.
- The largest Concert Pharmaceuticals, Inc. buyer in Q3 2016 was Alyeska Investment Group, an estimated $3.61M added.
- The largest Concert Pharmaceuticals, Inc. seller in Q3 2016 was Senzar Asset Management, an estimated $2.5M sold.
Based on aggregated 13F filings for Q3 2016.